Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $4.79 Average Price Target from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received an average rating of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $4.79.

Separately, StockNews.com began coverage on shares of Marinus Pharmaceuticals in a research report on Saturday. They issued a “sell” rating for the company.

Marinus Pharmaceuticals Price Performance

Shares of Marinus Pharmaceuticals stock opened at $0.55 on Friday. The business has a 50-day simple moving average of $0.55 and a 200 day simple moving average of $0.59. The firm has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $1.97.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MRNS. World Investment Advisors LLC bought a new stake in Marinus Pharmaceuticals in the third quarter worth about $104,000. Virtu Financial LLC purchased a new position in Marinus Pharmaceuticals in the fourth quarter valued at approximately $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Marinus Pharmaceuticals during the fourth quarter valued at $54,000. JPMorgan Chase & Co. raised its stake in shares of Marinus Pharmaceuticals by 1,968.5% in the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the period. Finally, Deltec Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter valued at $107,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.